Eyebiotech Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.eyebiotech.com
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- EyeBiotech Ltd.
- Target Recruit Count
- 960
- Registration Number
- NCT06957080
- Locations
- 🇺🇸
Bakersfield, CA, Bakersfield, California, United States
🇺🇸Modesto, CA, Modesto, California, United States
🇺🇸Redlands, CA, Redlands, California, United States
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Phase 1
Recruiting
- Conditions
- Diabetic Macular Edema (DME)Neovascular Age-related Macular Degeneration (NVAMD)BRVO - Branch Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- EyeBiotech Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT06664502
- Locations
- 🇺🇸
Lemont, IL, Lemont, Illinois, United States
🇺🇸Asheville, NC, Asheville, North Carolina, United States
🇺🇸Wake Forest, NC, Wake Forest, North Carolina, United States
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- EyeBiotech Ltd.
- Target Recruit Count
- 960
- Registration Number
- NCT06571045
- Locations
- 🇸🇰
Zilina, Slovakia, Žilina, Slovakia
🇺🇸Scottsdale, Scottsdale, Arizona, United States
🇺🇸Fayetteville, Arkansas, Fayetteville, Arkansas, United States
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
Phase 1
Completed
- Conditions
- Neovascular Age-related Macular Degeneration (NVAMD)Diabetic Macular Edema (DME)
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- EyeBiotech Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT05919693
- Locations
- 🇺🇸
San Antonio, TX, San Antonio, Texas, United States
🇦🇷Ciudad Autonoma Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
🇺🇸Lakewood, CO, Lakewood, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath